Orlov Nicole Schaeffer Sells 76,520 Shares of Insmed (NASDAQ:INSM) Stock

Key Points

• Insmed insider Orlov Nicole Schaeffer sold 76,520 shares of the company's stock for a total of $11,129,834, significantly reducing their stake by 67.73%.
• The company's stock recently traded down to $143.14, with a market cap of $30.26 billion and a fifty-two week high of $149.08.
• Insmed reported a quarterly EPS of ($1.70), missing analysts' expectations and resulting in a negative net margin of 259.82%, despite an 18.9% increase in revenue year-over-year.

Insmed, Inc. (NASDAQ:INSM - Get Free Report) insider Orlov Nicole Schaeffer sold 76,520 shares of the firm's stock in a transaction that occurred on Friday, September 12th. The shares were sold at an average price of $145.45, for a total transaction of $11,129,834.00. Following the transaction, the insider owned 36,461 shares in the company, valued at $5,303,252.45. This represents a 67.73% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.

Insmed Price Performance

Shares of NASDAQ INSM traded down $2.79 during mid-day trading on Monday, reaching $143.14. 1,977,691 shares of the company traded hands, compared to its average volume of 2,765,134. Insmed, Inc. has a fifty-two week low of $60.40 and a fifty-two week high of $149.08. The company has a debt-to-equity ratio of 0.45, a current ratio of 6.68 and a quick ratio of 6.33. The firm has a market cap of $30.26 billion, a PE ratio of -25.07 and a beta of 0.97. The stock has a fifty day simple moving average of $119.40 and a 200-day simple moving average of $92.09.

Insmed (NASDAQ:INSM - Get Free Report) last posted its quarterly earnings data on Thursday, August 7th. The biopharmaceutical company reported ($1.70) EPS for the quarter, missing analysts' consensus estimates of ($1.30) by ($0.40). Insmed had a negative net margin of 259.82% and a negative return on equity of 195.37%. The company had revenue of $107.42 million for the quarter, compared to analyst estimates of $104.06 million. During the same quarter in the prior year, the business earned ($1.94) EPS. Insmed's revenue was up 18.9% compared to the same quarter last year. Insmed has set its FY 2025 guidance at EPS. Equities research analysts anticipate that Insmed, Inc. will post -4.56 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

INSM has been the topic of a number of research analyst reports. Morgan Stanley raised their price objective on shares of Insmed from $126.00 to $144.00 and gave the company an "equal weight" rating in a research note on Thursday, August 21st. Jefferies Financial Group raised their price objective on shares of Insmed from $129.00 to $148.00 and gave the company a "buy" rating in a research note on Wednesday, August 13th. HC Wainwright raised their target price on shares of Insmed from $90.00 to $120.00 and gave the stock a "buy" rating in a report on Wednesday, June 11th. Bank of America raised their target price on shares of Insmed from $94.00 to $109.00 and gave the stock a "buy" rating in a report on Wednesday, June 11th. Finally, Royal Bank Of Canada raised their target price on shares of Insmed from $108.00 to $120.00 and gave the stock an "outperform" rating in a report on Friday, August 8th. Sixteen analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company's stock. Based on data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $139.86.

Hedge Funds Weigh In On Insmed

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Vanguard Group Inc. boosted its stake in Insmed by 0.3% in the 1st quarter. Vanguard Group Inc. now owns 18,268,122 shares of the biopharmaceutical company's stock worth $1,393,675,000 after purchasing an additional 49,149 shares during the period. Price T Rowe Associates Inc. MD boosted its stake in shares of Insmed by 1.7% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 12,923,541 shares of the biopharmaceutical company's stock valued at $985,938,000 after buying an additional 219,131 shares during the period. Adage Capital Partners GP L.L.C. boosted its stake in shares of Insmed by 109.2% during the 1st quarter. Adage Capital Partners GP L.L.C. now owns 3,446,944 shares of the biopharmaceutical company's stock valued at $262,967,000 after buying an additional 1,799,382 shares during the period. Artisan Partners Limited Partnership boosted its stake in shares of Insmed by 3.0% during the 2nd quarter. Artisan Partners Limited Partnership now owns 3,314,341 shares of the biopharmaceutical company's stock valued at $333,555,000 after buying an additional 97,073 shares during the period. Finally, Alliancebernstein L.P. boosted its stake in shares of Insmed by 2.5% during the 1st quarter. Alliancebernstein L.P. now owns 2,423,513 shares of the biopharmaceutical company's stock valued at $184,890,000 after buying an additional 59,952 shares during the period.

Insmed Company Profile

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.